Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Ed Mathers

Thursday, December 7, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ed Mathers has been a board member since 2016 and is a General Partner at New Enterprise Associates. He has a strong background in healthcare investments and previously held leadership roles at MedImmune. Mathers also serves on the boards of multiple biopharma companies, showcasing his extensive industry involvement.
Price reaction · baseline $4.05 (2023-12-07T19:50:00.000Z) · hit during market hours · 6 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Mr. Mathers has extensive experience in venture capital and healthcare.
  • He has been a board member since 2016, indicating stability.
  • His leadership roles at various companies highlight his influence in the industry.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

Mr. Mathers has served as a member of our board of directors since 2016. Mr. Mathers has served as a General Partner at New Enterprise Associates (NEA), a private venture capital firm focusing on technology and healthcare investments, since 2019, and prior to that served as partner at NEA from 2008 to 2019. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune and led its venture capital subsidiary, MedImmune Ventures. Mr. Mathers currently serves on the board of directors of Affinia Therapeutics, Akouos, Amplyx Pharmaceuticals, Inozyme Pharma, MBX Biosciences, Mirum Pharmaceuticals, ObsEva SA, Reneo Pharmaceuticals, Rhythm Pharmaceuticals, Synlogic, (formerly known as Mirna Therapeutics) and Trevi Therapeutics.
Mr. Mathers earned his B.S. in Chemistry from North Carolina State University.

Frequently Asked Questions

What is Ed Mathers' role at SNTI?

Ed Mathers has been a member of SNTI's board of directors since 2016.

What experience does Ed Mathers have?

He has extensive experience in venture capital and healthcare investments.

Which companies does Ed Mathers serve on the board?

He serves on the boards of several companies, including Affinia Therapeutics and Rhythm Pharmaceuticals.

Where did Ed Mathers earn his degree?

He earned his B.S. in Chemistry from North Carolina State University.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare Ed Mathers New Enterprise Associates MedImmune biopharma
Last updated: Dec 7, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →